575 related articles for article (PubMed ID: 20709000)
1. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.
Morelon E; Pouteil Noble C; Daoud S; Cahen R; Goujon-Henry C; Weber F; Laurent PE; Kaiserlian D; Nicolas JF
Vaccine; 2010 Oct; 28(42):6885-90. PubMed ID: 20709000
[TBL] [Abstract][Full Text] [Related]
2. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
Leroux-Roels I; Vets E; Freese R; Seiberling M; Weber F; Salamand C; Leroux-Roels G
Vaccine; 2008 Dec; 26(51):6614-9. PubMed ID: 18930093
[TBL] [Abstract][Full Text] [Related]
3. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
[TBL] [Abstract][Full Text] [Related]
4. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
Arnou R; Icardi G; De Decker M; Ambrozaitis A; Kazek MP; Weber F; Van Damme P
Vaccine; 2009 Dec; 27(52):7304-12. PubMed ID: 19849996
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of intradermal influenza vaccine in children.
Esposito S; Daleno C; Picciolli I; Tagliaferri L; Scala A; Prunotto G; Montinaro V; Galeone C; Principi N
Vaccine; 2011 Oct; 29(44):7606-10. PubMed ID: 21855592
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
11. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
[TBL] [Abstract][Full Text] [Related]
12. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
[TBL] [Abstract][Full Text] [Related]
14. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.
Manuel O; Humar A; Berutto C; Ely L; Giulieri S; Lien D; Meylan PR; Weinkauf J; Pascual M; Nador R; Aubert JD; Kumar D
J Heart Lung Transplant; 2011 Jun; 30(6):679-84. PubMed ID: 21377898
[TBL] [Abstract][Full Text] [Related]
15. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
[TBL] [Abstract][Full Text] [Related]
19. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
20. Serum antibody responses after intradermal vaccination against influenza.
Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
